NEW DELHI, June 3: Drug firm Suven Life Sciences has been granted a patent each by Israel and Mexico for a drug used for the treatment of neuro-degenerative diseases.
In a BSE filing today, Suven Life said it has been granted “one product patent from Israel and one product patent from Mexico corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases”.
The patents are valid till 2032, the company added.
Suven said the granted claims of the patents…Are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has a total of 10 granted patents from Israel and 21 from Mexico.
“These granted patents are exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like phase-I or phase-II,” Suven said.
(PTI)
Trending Now
E-Paper
Follow our WhatsApp channel